Equity Research, Broker Reports, and media content on THROMBOGENICS NV

  • Access the latest forecasts, broker valuations, multiples, and video content from the city about THROMBOGENICS NV
  • See live updates from analysts, company announcements, and other news in a personalised/single dashboard

Research, Charts & Company Announcements

Research Tree provides access to ongoing research coverage, media content and regulatory news on THROMBOGENICS NV. We currently have 0 research reports from 0 professional analysts.

Open
3.10
Volume
0.0m
Range
3.10/3.10
Market Cap
112,253,384m
52 Week
2.50/3.90
Date Source Announcement
20Apr17 06:30 GNW ThromboGenics Achieves Important Milestone in the Development of THR-149, A Novel Plasma Kallikrein Inhibitor for Diabetic Macular Edema
01Mar16 07:00 GNW ThromboGenics to Host R&D Investor Meeting on Novel Disease-Modifying Approaches for Diabetic Eye Disease 18 March in London
13Jan16 06:30 GNW ThromboGenics Enrolls First Patient in Phase II CIRCLE Trial
07Jan16 06:30 GNW Oncurious NV Announces FDA Acceptance of Investigational New Drug (IND) Application for a Phase I/IIa Study with TB-403 for the Treatment of Pediatric Brain Tumors
18Nov15 16:40 GNW ThromboGenics Reports Positive 2 Year Results from the OASIS Study with JETREA® (ocriplasmin) for the treatment of Symptomatic VMA/VMT and Macular Hole
13Nov15 06:30 GNW ThromboGenics Presents Full OASIS JETREA Trial Data Analysis (incl ERG) and Further Real World Clinical Data at Upcoming AAO 2015 in Las Vegas
12Nov15 06:30 GNW ThromboGenics Announces FDA Acceptance of Investigational New Drug (IND) Application for Phase II Study with JETREA® for the Treatment of Non-Proliferative Diabetic Retinopathy (CIRCLE)
  • Frequency of research reports

     

  • Research reports on

    THROMBOGENICS NV

  • Providers covering

    THROMBOGENICS NV